Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. It also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Proprietary Products segment focuses on the research, development, and manufacture of differentiated formulations for dermatology and neurology therapeutic areas. It also provides a portfolio of in-licensed dermatology products. As of March 31, 2018, this segment had 13 active products development programs pipeline that are in various stages of development. The company's therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, pain management, oncology, dermatology, urology, and nephrology. It has collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology; and collaboration agreement with Merck Serono to co-develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies. Dr. Reddy's Laboratories Limited was founded in 1984 and is headquartered in Hyderabad, India.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone91-40-4900-2900
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.20 billion
Profitability
Miscellaneous
Employees23,524
OptionableOptionable
Dr.Reddy's Laboratories (NYSE:RDY) Frequently Asked Questions
What is Dr.Reddy's Laboratories' stock symbol?
Dr.Reddy's Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "RDY."
How were Dr.Reddy's Laboratories' earnings last quarter?
Dr.Reddy's Laboratories Ltd (NYSE:RDY) released its quarterly earnings results on Friday, October, 26th. The company reported $0.42 EPS for the quarter. The company had revenue of $524 million for the quarter, compared to analyst estimates of $522.22 million. Dr.Reddy's Laboratories had a return on equity of 13.14% and a net margin of 10.62%. View Dr.Reddy's Laboratories' Earnings History.
When is Dr.Reddy's Laboratories' next earnings date?
What is the consensus analysts' recommendation for Dr.Reddy's Laboratories?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dr.Reddy's Laboratories in the last year. There are currently 1 sell rating for the stock, resulting in a consensus recommendation of "Sell." View Analyst Ratings for Dr.Reddy's Laboratories.
Has Dr.Reddy's Laboratories been receiving favorable news coverage?
Media coverage about RDY stock has trended very positive this week, according to InfoTrie Sentiment. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Dr.Reddy's Laboratories earned a coverage optimism score of 3.2 on InfoTrie's scale. They also gave headlines about the company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Who are some of Dr.Reddy's Laboratories' key competitors?
Some companies that are related to Dr.Reddy's Laboratories include Shiseido (SSDOY), Teva Pharmaceutical Industries (TEVA), BioMarin Pharmaceutical (BMRN), UCB (UCBJF), Mylan (MYL), Ono Pharmaceutical (OPHLF), GRIFOLS S A/S (GRFS), Merck KGaA (MKGAF), Genmab A/S (GNMSF), Beigene (BGNE), Alnylam Pharmaceuticals (ALNY), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Nektar Therapeutics (NKTR) and Ionis Pharmaceuticals (IONS).
Who are Dr.Reddy's Laboratories' key executives?
Dr.Reddy's Laboratories' management team includes the folowing people:
- Mr. Gunupati Venkateswara Prasad, Co-Chairman, MD, CEO & Member of Management Council (Age 58)
- Mr. Kallam Satish Reddy, Chairman & Member of the Management Council (Age 51)
- Mr. Saumen Chakraborty, Pres, CFO, Global Head of IT & Bus. Process Excellence and Member of the Mgmt Council (Age 57)
- Mr. M. V. Ramana, CEO & Head of Branded Markets - India & Emerging Countries and Member of Management Council (Age 49)
- Mr. Ganadhish Kamat, Exec. VP, Global Head of Quality & Member of Management Council (Age 55)
Who are Dr.Reddy's Laboratories' major shareholders?
Dr.Reddy's Laboratories' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Quadrant Capital Group LLC (0.00%).
Which major investors are buying Dr.Reddy's Laboratories stock?
RDY stock was acquired by a variety of institutional investors in the last quarter, including Quadrant Capital Group LLC.
How do I buy shares of Dr.Reddy's Laboratories?
Shares of RDY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Dr.Reddy's Laboratories' stock price today?
One share of RDY stock can currently be purchased for approximately $37.04.
How big of a company is Dr.Reddy's Laboratories?
Dr.Reddy's Laboratories has a market capitalization of $6.15 billion and generates $2.20 billion in revenue each year. The company earns $151 million in net income (profit) each year or $1.01 on an earnings per share basis. Dr.Reddy's Laboratories employs 23,524 workers across the globe.
What is Dr.Reddy's Laboratories' official website?
How can I contact Dr.Reddy's Laboratories?
Dr.Reddy's Laboratories' mailing address is 8-2-337 ROAD NO.3 BANJARA HILLS, HYDERABAD K7, 500-034. The company can be reached via phone at 91-40-4900-2900 or via email at [email protected]
MarketBeat Community Rating for Dr.Reddy's Laboratories (NYSE RDY)
MarketBeat's community ratings are surveys of what our community members think about Dr.Reddy's Laboratories and other stocks. Vote "Outperform" if you believe RDY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RDY will underperform the S&P 500 over the long term. You may vote once every thirty days.
